67980-77-2

Basic information

• Product Name: 1-(3-Pyridinyl)piperazine
• Synonyms: 1-PYRIDIN-3-YL-PIPERAZINE;1-(3-Pyridinyl)piperazine;1-pyridin-3-ylpiperazine(SALTDATA: 2HBr);1-pyridin-3-ylpiperazine 2HBr;BUTTPARK 82\08-04;CHEMBRDG-BB 4004211
• CAS NO: 67980-77-2
• Molecular Formula: C₉H₁₃N₃
• Molecular Weight: 163.22
• Product Categories: pharmacetical
• Mol File: 67980-77-2.mol
• Article Data: 21

Chemical Properties

• Melting Point: 48-52°C
• Boiling Point: 314.396 °C at 760 mmHg
• Flash Point: 143.942 °C
• Appearance: /
• Density: 1.081 g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.547
• Storage Temp.: 2-8°C(protect from light)
• PKA: 8.70±0.10(Predicted)
• CAS DataBase Reference: 1-(3-Pyridinyl)piperazine(CAS DataBase Reference)
• NIST Chemistry Reference: 1-(3-Pyridinyl)piperazine(67980-77-2)
• EPA Substance Registry System: 1-(3-Pyridinyl)piperazine(67980-77-2)

Safety Data

• Hazardous Substances Data: 67980-77-2(Hazardous Substances Data)

Usage

General Description

1-(3-Pyridinyl)piperazine, also known as 3-PP or mCPP, is a chemical compound that belongs to the class of piperazine derivatives. It is used as a research chemical and is also known as a psychoactive drug with stimulant and entactogenic effects. 1-(3-Pyridinyl)piperazine has been found to act as a serotonin receptor agonist and a norepinephrine reuptake inhibitor, leading to its stimulant effects. It has been associated with various side effects and has been banned in some countries due to its potential for abuse and adverse health effects. The compound continues to be studied for its pharmacological properties and potential medical applications.

InChI:InChI=1/C9H13N3/c1-2-9(8-11-3-1)12-6-4-10-5-7-12/h1-3,8,10H,4-7H2

Upstream product

• 110-85-0 piperazine 
• 626-55-1 3-Bromopyridine 
• 13480-30-3 1-benzyl-4-(3'-pyridinyl)piperazine 
• 223797-47-5 1-(pyridin-3-yl)-4-tert-butoxycarbonylpiperazine 
• 462-08-8 pyridin-3-ylamine 
• 821-48-7 bis-(2-chloroethyl)amine hydrochloride 
• 865-48-5 sodium t-butanolate 
• 13716-12-6 tri-tert-butyl phosphine 
• 372-47-4 3-Fluoropyridine 

Downstream Products

• 223794-26-1 1-methyl-4-(pyridin-3-yl)piperazine 
• 112940-59-7 1-(4-nitrophenyl)-4-pyridin-3-ylpiperazine 
• 854159-12-9 1-(3-pyridyl)-4-tritylpiperazine 
• 223797-47-5 1-(pyridin-3-yl)-4-tert-butoxycarbonylpiperazine 
• 854159-22-1 1-(2-chloro-3-pyridyl)-4-tritylpiperazine 
• 854159-15-2 1-(2-methylsulfanyl-3-pyridyl)-4-tritylpiperazine 
• 854159-25-4 1-(2-bromo-3-pyridyl)-4-tritylpiperazine 
• 854159-66-3 1-(2-iodo-3-pyridyl)-4-tritylpiperazine 
• 854159-35-6 1-(2-bromo-6-methylsulfanyl-3-pyridyl)-4-tritylpiperazine 
• 854159-36-7 1-(2-iodo-6-methylsulfanyl-3-pyridyl)-4-tritylpiperazine 
• 854159-33-4 1-(2-(2,2-dimethyl-1-hydroxypropyl)-3-pyridyl)-4-tritylpiperazine 
• 854159-30-1 1-(2-(2,2-dimethyl-1-oxopropyl)-3-pyridyl)-4-tritylpiperazine 
• 854159-37-8 1-(2-methylsulfanyl-6-benzoyl-3-pyridyl)-4-tritylpiperazine 
• 112940-60-0 4-(4-pyridin-3-ylpiperazin-1-yl)aniline 

Relevant articles and documents

Dopamine D4 ligands and models of receptor activation: 2-(4-pyridin-2-ylpiperazin-1-ylmethyl)-1H-benzimidazole and related heteroarylmethylarylpiperazines exhibit a substituent effect responsible for additional efficacy tuning.

A series of subtype selective dopamine D(4) receptor ligands from the hetroarylmethylphenylpiperazine class have been discovered that exhibit a remarkable structure-activity relationship (SAR), revealing a substituent effect in which regiosubstitution on the terminal arylpiperazine ring can modulate functional or intrinsic activity. Other structure-dependent efficacy studies in the dopamine D(4) field have suggested a critical interaction of the heteroarylmethyl moiety with specific protein microdomains in controlling intrinsic activity. Our studies indicate that for some binding orientations, the phenylpiperazine moiety also plays a key role in determining efficacy. These data also implicate a kinetic or efficiency term, contained within measured functional affinities for agonists, which support a sequential binding and conformational stabilization model for receptor activation. The structural similarity between partial agonist and antagonist, within this subset of ligands, and lack of bioisosterism for this substituent effect are key phenomena for these hypotheses.

Exploration of the molecular architecture of the orthosteric binding site in the α4β2 nicotinic acetylcholine receptor with analogs of 3-(dimethylamino)butyl dimethylcarbamate (DMABC) and 1-(pyridin-3-yl)-1,4-diazepane

X-ray crystal structures of acetylcholine binding proteins (AChBPs) have revealed two different possible extensions to the classical ligand binding pocket known to accommodate various nicotinic agonists. One of the pockets is limited in size while the oth

NOVEL COMPOUNDS

This invention relates to compounds of formula I their use as positive allosteric modulators of mGlu5 receptor activity, pharmaceutical compositions containing the same, and methods of using the same as agents for treatment and/or prevention of neurological and psychiatric disorders associated with glutamate dysfunction such as schizophrenia or cognitive decline such as dementia or cognitive impairment. A, B, Ar, R1, R2, R3 have meanings given in the description.